Here, we performed a randomized phase II trial for locally advanced and high risk HER2-negative breast cancer to assess the efficacy and toxicity of the TX regimen using a combination of docetaxel and epirubicin (TE) as the standard comparator. This evidence concerns the gene ERBB2 and breast carcinoma.